Could a Stop-Smoking drug fight dialysis fatigue?
NCT ID NCT06609343
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This early-stage study tests whether bupropion, a medicine used for smoking cessation and depression, can reduce severe tiredness in people with end-stage kidney disease on dialysis. Sixteen participants will take bupropion three times a week for 8 weeks and report their fatigue levels. The goal is to find a safe, effective way to improve quality of life for these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Dialysis Medical Center (DMC)
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Could a daily electrolyte drink sharpen your mind?
- Can a gentle brain current recharge stroke survivors?
- Could a himalayan pepper sharpen your gaming edge?
- Can a basketball workout reveal the Body's hidden fatigue signals?
- What does life feel like for children with a rare birth defect? a new study asks